Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 6/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18795317 | 1.00 | MDM2 (0.54) | MDM2MDM4TP53TLR2TNF | |
| SCHEMBL29818551 | 0.94 | MDM4 (0.54) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL29984428 | 0.90 | HDAC1 (0.54) | MDM2MDM4TP53TLR2TNF | |
| SCHEMBL18818374 | 0.90 | HDAC1 (0.54) | MDM2MDM4TP53TLR2TNF | |
| SCHEMBL13517728 | 0.89 | MDM2 (0.53) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL13517725 | 0.89 | MDM2 (0.53) | MDM2MDM4TP53TLR2CASP3 | |
| SCHEMBL31000735 | 0.88 | MDM4 (0.55) | MDM2MDM4TP53TLR2TNF | |
| SCHEMBL31165326 | 0.88 | MDM4 (0.55) | MDM2MDM4TP53TLR2TNF | |
| SCHEMBL29401864 | 0.88 | MDM4 (0.55) | MDM2MDM4TP53TLR2TNF | |
| SCHEMBL19899314 | 0.88 | MDM4 (0.55) | MDM2MDM4TP53TLR2TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2024-06-18 | — | — | US | disclosed |
| US-11505573-B2 | Peptide macrocycles against Acinetobacter baumannii | HOFFMANN-LA ROCHE INC. (US) | 2022-11-22 | — | — | US | disclosed |
| CN-108350028-B | Peptide macrocycles against Acinetobacter baumannii | 豪夫迈·罗氏有限公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3773655-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | H. Hoffnabb-La Roche Ag (CH) | 2021-02-17 | — | — | EP | disclosed |
| WO-2019185572-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | F. HOFFMANN-LA ROCHE AG (CH) | 2019-10-03 | — | — | WO | disclosed |
| US-20190300569-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | HOFFMANN-LA ROCHE INC. (US) | 2019-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190300569-A1 | PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | VIP, CXCL10, ARG1 | MDM2 3774/4885MDM4 3954/4885TP53 3060/4885 |
| US-12012466-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, ARG1, CX3CR1 | MDM2 4288/4885MDM4 3771/4885TP53 3724/4885 |
| US-11505573-B2 | Peptide macrocycles against Acinetobacter baumannii | VIP, CXCL10, ARG1 | MDM2 3774/4885MDM4 3954/4885TP53 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.